nach oben

Cardiovascular Drugs and Therapy

Erschienen in:

01.04.2008

Linking the Cardiomyocyte Circadian Clock to Myocardial Metabolism

verfasst von: David J. Durgan, Martin E. Young

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The energetic demands imposed upon the heart vary dramatically over the course of the day. In the face of equally commanding oscillations in the neurohumoral mileu, the heart must respond both rapidly and appropriately to its diurnal environment, for the survival of the organism. A major response of the heart to alterations in workload, nutrients, and various neurohumoral stimuli is at the level of metabolism. Failure of the heart to achieve adequate metabolic adaptation results in contractile dysfunction.

Discussion

Substantial evidence is accumulating which suggests that a transcriptionally based timekeeping mechanism known as the circadian clock plays a role in mediating myocardial metabolic rhythms. Here, we provide an overview of our current knowledge regarding the interplay between the circadian clock within the cardiomyocyte and myocardial metabolism. This includes a particular focus on circadian clock mediated regulation of endogenous energy stores, as well as those mechanisms orchestrating circadian rhythms in metabolic gene expression.

Conclusion

An essential need to elucidate fully the functions of this molecular mechanism in the heart remains.

Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation. 1989;79:733–43.PubMed

Aronow WS, Ahn C. Circadian variation of death from congestive heart failure after myocardial infarction in patients >60 years of age. Am J Cardiol. 2003;92:1354–5.PubMedCrossRef

Carson PA, O’Connor CM, Miller AB, et al. Circadian rhythm and sudden death in heart failure: results from Prospective Randomized Amlodipine Survival Trial. J Am Coll Cardiol. 2000;36:541–6.PubMedCrossRef

Mukamal KJ, Muller JE, Maclure M, Sherwood JB, Mittleman MA. Increased risk of congestive heart failure among infarctions with nighttime onset. Am Heart J. 2000;140:438–42.PubMedCrossRef

Prinz PN, Halter J, Benedetti C, Raskind M. Circadian variation of plasma catecholamines in young and old men: relation to rapid eye movement and slow wave sleep. J Clin Endocrinol Metab. 1979;49:300–4.PubMedCrossRef

Degaute JP, van de Borne P, Linkowski P, Van Cauter E. Quantitative analysis of the 24-hour blood pressure and heart rate patterns in young men. Hypertension. 1991;18:199–210.PubMed

Turton MB, Deegan T. Circadian variations of plasma catecholamine, cortisol and immunoreactive insulin concentrations in supine subjects. Clin Chim Acta. 1974;55:389–97.PubMedCrossRef

Richards AM, Nicholls MG, Espiner EA, Ikram H, Cullens M, Hinton D. Diurnal patterns of blood pressure, heart rate and vasoactive hormones in normal man. Clin Exp Hypertens. 1986;8:153–66.CrossRef

Young ME. The circadian clock within the heart: potential influence on myocardial gene expression, metabolism, and function. Am J Physiol Heart Circ Physiol. 2006;290:H1–H16.PubMedCrossRef

10.

Reilly DF, Westgate EJ, FitzGerald GA. Peripheral circadian clocks in the vasculature. Arterioscler Thromb Vasc Biol. 2007;27:1694–705.PubMedCrossRef

11.

Takeda N, Maemura K. Chronobiology of acute myocardial infarction molecular biology. Biol Rhythm Res. 2007;38:233–45.CrossRef

12.

Clark H, Carling D, Saggerson D. Covalent activation of heart AMP-activated protein kinase in response to physiological concentrations of long-chain fatty acids. Eur J Biochem. 2004;271:2215–24.PubMedCrossRef

13.

Longnus SL, Wambolt RB, Barr RL, Lopaschuk GD, Allard MF. Regulation of myocardial fatty acid oxidation by substrate supply. Am J Physiol Heart Circ Physiol. 2001;281:H1561–H1567.PubMed

14.

Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1:785–9.PubMedCrossRef

15.

van der Lee KA, Vork MM, De Vries JE, et al. Long-chain fatty acid-induced changes in gene expression in neonatal cardiac myocytes. J Lipid Res. 2000;41:41–7.PubMed

16.

Campbell FM, Kozak R, Wagner A, et al. A role for PPAR{alpha} in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPAR{alpha} are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem. 2002;277:4098–103.PubMedCrossRef

17.

Young ME, Goodwin GW, Ying J, et al. Regulation of cardiac and skeletal muscle malonyl-CoA decarboxylase by fatty acids. Am J Physiol Endocrinol Metab. 2001;280:E471–E479.PubMed

18.

Wu P, Sato J, Zhao Y, Jaskiewicz J, Popov KM, Harris RA. Starvation and diabetes increase the amount of pyruvate dehydrogenase kinase isoenzyme 4 in rat heart. Biochem J. 1998;329:197–201.PubMed

19.

Barger PM, Kelly DP. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med. 2000;10:238–45.PubMedCrossRef

20.

Young ME, McNulty PH, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: Part II: potential mechanisms. Circulation. 2002;105:1861–70.PubMedCrossRef

21.

Cheng L, Ding G, Qin Q, et al. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med. 2004;10:1245–50.PubMedCrossRef

22.

Osorio JC, Stanley WC, Linke A, et al. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation. 2002;106:606–12.PubMedCrossRef

23.

Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DP. Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J Clin Invest. 2000;105:1723–30.PubMedCrossRef

24.

Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation. 2001;104:2923–31.PubMedCrossRef

25.

Young ME, Guthrie PH, Razeghi P, et al. Impaired long chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart. Diabetes. 2002;51:2587–95.PubMedCrossRef

26.

Zhou YT, Grayburn P, Karim A, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A. 2000;97:1784–9.PubMedCrossRef

27.

Sharma S, Adrogue JV, Golfman L, et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 2004;18:1692–700.PubMedCrossRef

28.

McGavock JM, Lingvay I, Zib I, et al. Cardiac steatosis in diabetes mellitus. A 1H-Magnetic resonance spectroscopy study. Circulation. 2007;116:1170–5.PubMedCrossRef

29.

Young ME, Razeghi P, Cedars AM, Guthrie PH, Taegtmeyer H. Intrinsic diurnal variations in cardiac metabolism and contractile function. Circ Res 2001;89:1199–208.PubMedCrossRef

30.

Durgan DJ, Moore MW, Ha NP, et al. Circadian rhythms in myocardial metabolism and contractile function: influence of workload and oleate. Am J Physiol Heart Circ Physiol. 2007;293:H2385–H2393.PubMedCrossRef

31.

Goodwin GW, Taylor CS, Taegtmeyer H. Regulation of energy metabolism of the heart during acute increase in heart work. J Biol Chem. 1998;273:29530–9.PubMedCrossRef

32.

Edery I. Circadian rhythms in a nutshell. Physiol Genomics. 2000;3:59–74.PubMed

33.

Duffield GE. DNA microarray analysis of circadian timing: the genomic basis of biological time. J Neuroendocrinol. 2003;15:991–1002.PubMedCrossRef

34.

Lowrey PL, Takahashi H. Mammalian circadian biology: elucidating genome-wide levels of temporal organization. Annu Rev Genomics Hum Genet. 2004;5:407–41.PubMedCrossRef

35.

Oishi K, Miyazaki K, Kadota K, et al. Genome-wide expression analysis of mouse liver reveals CLOCK-regulated circadian output genes. J Biol Chem. 2003;278:41519–27.PubMedCrossRef

36.

Reddy AB, Karp NA, Maywood ES, et al. Circadian orchestration of the hepatic proteome. Curr Biol. 2006;16:1107–15.PubMedCrossRef

37.

Martino T, Arab S, Straume M, et al. Day/night rhythms in gene expression of the normal murine heart. J Mol Med. 2004;82:256–64.PubMedCrossRef

38.

Storch KF, Lipan O, Leykin I, et al. Extensive and divergent circadian gene expression in liver and heart. Nature. 2002;417:78–83.PubMedCrossRef

39.

Durgan DJ, Trexler NA, Egbejimi O, et al. The circadian clock within the cardiomyocyte is essential for responsiveness of the heart to fatty acids. J Biol Chem. 2006;281:24254–69.PubMedCrossRef

40.

Boudina S, Sena S, O’Neill BT, Tathireddy P, Young ME, Abel ED. Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation. 2005;112:2686–95.PubMedCrossRef

41.

Burkhoff D, Weiss R, Schulman S, Kalil-Filho R, Wannenburg T, Gerstenblith G. Influence of metabolic substrate on rat heart function and metabolism at different coronary flows. Am J Physiol. 1991;261:H741–H750.PubMed

42.

Kjekshus J, Mjos O. Effect of free fatty acids on myocardial function and metabolism in the ischemic dog heart. J Clin Invest. 1972;51:1767.PubMedCrossRef

43.

Mjos OD. Effects of free fatty acids on myocardial oxygen consumption in intact dogs. J Clin Invest. 1971;50:1386–9.PubMedCrossRef

44.

Vincent G, Bouchard B, Khairallah M, Des Rosiers C. Differential modulation of citrate synthesis and release by fatty acids in perfused working rat hearts. Am J Physiol Heart Circ Physiol. 2004;286:H257–H266.PubMedCrossRef

45.

Marquez S, Crespo P, Carlini V, et al. The metabolism of phospholipids oscillates rhythmically in cultures of fibroblasts and is regulated by the clock protein PERIOD1. FASEB J. 2004;18:519–21.PubMed

46.

Lake AC, Sun Y, Li JL, et al. Expression, regulation, and triglyceride hydrolase activity of Adiponutrin family members. J Lipid Res. 2005;46:2477–87.PubMedCrossRef

47.

Stone SJ, Myers HM, Watkins SM, et al. Lipopenia and skin barrier abnormalities in DGAT2-deficient mice. J Biol Chem. 2004;279:11767–76.PubMedCrossRef

48.

Coleman RA, Lee DP. Enzymes of triglyceride synthesis and their regulation. Prog Lipid Res. 2004;43:134–76.PubMedCrossRef

49.

Bray MS, Shaw CA, Moore MWS, et al. Disruption of the circadian clock within the cardiomyocyte influences myocardial contractile function, metabolism, and gene expression. Am J Physiol Heart Circ Physiol. (in press).

50.

Ishikawa K, Shimazu T. Daily rhythms of glycogen synthetase and phosphorylase activities in rat liver: influence of food and light. Life Sci. 1976;19:1873–8.PubMedCrossRef

51.

Stavinoha MA, RaySpellicy JW, Hart-Sailors ML, Mersmann HJ, Bray MS, Young ME. Diurnal variations in the responsiveness of cardiac and skeletal muscle to fatty acids. Am J Physiol. 2004;287:E878–E887.CrossRef

52.

Forman BM, Chen J, Blumberg B, et al. Cross-talk among ROR alpha 1 and the Rev-erb family of orphan nuclear receptors. Mol Endocrinol. 1994;8:1253–61.PubMedCrossRef

53.

Adelmant G, Beque A, Stehelin D, Laudet V. A functional Rev-erb alpha responsive element located in the human Rev-erb alpha promoter mediates a repressing activity. Proc Natl Aad Sci U S A. 1996;93:3553–8.CrossRef

54.

Dussault I, Giguere V. Differential regulation of the N-myc proto-oncogene by ROR alpha and RVR, two orphan members of the superfamily of nuclear hormone receptors. Mol Cell Biol. 1997;17:1860–7.PubMed

55.

Bois-Joyeux B, Chauvet C, Nacer-Cherif H, et al. Modulation of the far-upstream enhancer of the rat alpha-fetoprotein gene by members of the ROR alpha, Rev-erb alpha, and Rev-erb beta groups of monomeric orphan nuclear receptors. DNA Cell Biol 2000;19:589–99.PubMedCrossRef

56.

Raspe E, Duez H, Gervois P, et al. Transcriptional regulation of apolipoprotein C-III gene expression by the orphan nuclear receptor RORalpha. J Biol Chem 2001;276:2865–71.PubMedCrossRef

57.

Lau P, Nixon SJ, Parton RG, Muscat GE. RORalpha regulates the expression of genes involved in lipid homeostasis in skeletal muscle cells: caveolin-3 and CPT-1 are direct targets of ROR. J Biol Chem. 2004;279:36828–40.PubMedCrossRef

58.

Ramakrishnan SN, Lau P, Burke LJ, Muscat GE. Rev-erbbeta regulates the expression of genes involved in lipid absorption in skeletal muscle cells: evidence for cross-talk between orphan nuclear receptors and myokines. J Biol Chem. 2005;280:8651–9.PubMedCrossRef

59.

Preitner N, Damiola F, Lopez-Molina L, et al. The orphan nuclear receptor REV-ERBalpha controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell. 2002;110:251–60.PubMedCrossRef

60.

Ueda HR, Chen W, Adachi A, et al. A transcription factor response element for gene expression during the circadian night. Nature. 2002;418:534–9.PubMedCrossRef

61.

Gekakis N, Staknis D, Nguyen HB, et al. Role of the CLOCK protein in the mammalian circadian mechanism. Science. 1998;280:1564–9.PubMedCrossRef

62.

Hogenesch JB, Gu YZ, Jain S, Bradfield CA. The basic-helix-loop-helix-PAS orphan MOP3 forms transcriptionally active complexes with circadian and hypoxia factors. Proc Natl Aad Sci U S A. 1998;95:5474–9.CrossRef

63.

Dunlap JC. Molecular basis of circadian clocks. Cell. 1999;96:271–90.PubMedCrossRef

64.

Hardin PE. Transcription regulation within the circadian clock: the E-box and beyond. J Biol Rhythms. 2004;19:348–60.PubMedCrossRef

65.

Wijnen H, Young MW. Interplay of circadian clocks and metabolic rhythms. Annu Rev Genet. 2006;40:409–48.PubMedCrossRef

66.

Ripperger JA, Shearman LP, Reppert SM, Schibler U. CLOCK, an essential pacemaker component, controls expression of the circadian transcription factor DBP. Genes Dev. 2000;14:679–89.PubMed

67.

Falvey E, Fleury-Olela F, Schibler U. The rat hepatic leukemia factor (HLF) gene encodes two transcriptional activators with distinct circadian rhythms, tissue distributions and target preferences. EMBO J. 1995;14:4307–17.PubMed

68.

Fonjallaz P, Ossipow V, Wanner G, Schibler U. The two PAR leucine zipper proteins, TEF and DBP, display similar circadian and tissue-specific expression, but have different target promoter preferences. EMBO J. 1996;15:351–62.PubMed

69.

Mitsui S, Yamaguchi S, Matsuo T, Ishida Y, Okamura H. Antagonistic role of E4BP4 and PAR proteins in the circadian oscillatory mechanism. Genes Dev. 2001;15:995–1006.PubMedCrossRef

70.

Kung TA, Egbejimi O, Cui J, et al. Rapid attenuation of circadian clock gene oscillations in the rat heart following ischemia-reperfusion. J Mol Cell Cardiol. 2007;43:744–53.PubMedCrossRef

71.

Iitaka C, Miyazaki K, Akaike T, Ishida N. A role for glycogen synthase kinase-3beta in the mammalian circadian clock. J Biol Chem. 2005;280:29397–402.PubMedCrossRef

72.

Rutter J, Reick M, Wu LC, McKnight SL. Regulation of clock and NPAS2 DNA binding by the redox state of NAD cofactors. Science. 2001;293:510–4.PubMedCrossRef

73.

Oishi K, Shirai H, Ishida N. CLOCK is involved in the circadian transactivation of peroxisome proliferator-activated receptor alpha (PPARalpha) in mice. Biochem J. 2005;386:575–81.PubMedCrossRef

74.

Liu C, Li S, Liu T, Borjigin J, Lin JD. Transcriptional coactivator PGC-1alpha integrates the mammalian clock and energy metabolism. Nature. 2007;447:477–81.PubMedCrossRef

75.

Sonoda J, Mehl IR, Chong LW, Nofsinger RR, Evans RM. PGC-1beta controls mitochondrial metabolism to modulate circadian activity, adaptive thermogenesis, and hepatic steatosis. Proc Natl Acad Sci U S A. 2007;104:5223–8.PubMedCrossRef

76.

Lee SS, Pineau T, Drago J, et al. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol. 1995;15:3012–22.PubMed

77.

Aoyama T, Peters J, Iritani N, et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J Biol Chem. 1998;273:5678–84.PubMedCrossRef

78.

Djouadi F, Brandt JM, Weinheimer CJ, Leone TC, Gonzalez FJ, Kelly DP. The role of the peroxisome proliferator-activated receptor alpha (PPAR alpha) in the control of cardiac lipid metabolism. Prostaglandins Leukot Essent Fat Acids. 1999;60:339–43.CrossRef

79.

Finck BN, Kelly DP. Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease. Circulation. 2007;115:2540–8.PubMedCrossRef

80.

Kassam A, Capone JP, Rachubinski RA. Orphan nuclear hormone receptor RevErbalpha modulates expression from the promoter of the hydratase-dehydrogenase gene by inhibiting peroxisome proliferator-activated receptor alpha-dependent transactivation. J Biol Chem. 1999;274:22895–900.PubMedCrossRef

81.

Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science. 2001;294:1866–70.PubMedCrossRef

82.

Yang X, Downes M, Yu RT, et al. Nuclear receptor expression links the circadian clock to metabolism. Cell. 2006;126:801–10.PubMedCrossRef

83.

Giguere V, Yang N, Sequi P, Evans RM. Identification of a new class of steroid hormone receptors. Nature. 1988;331:91–4.PubMedCrossRef

84.

Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell. 2006;126:789–99.PubMedCrossRef

85.

Dufour CR, Wilson BJ, Huss JM, et al. Genome-wide orchestration of cardiac functions by the orphan nuclear receptors ERRalpha and gamma. Cell Metab. 2007;5:345–56.PubMedCrossRef

86.

Englund A, Behrens S, Wegscheider K, Rowland E. Circadian variation of malignant ventricular arrhythmias in patients with ischemic and nonischemic heart disease after cardioverter defibrillator implantation. European 7219 Jewel Investigators. J Am Coll Cardiol. 1999;34:1560–8.PubMedCrossRef

87.

Arntz HR, Willich SN, Oeff M, et al. Circadian variation of sudden cardiac death reflects age-related variability in ventricular fibrillation. Circulation. 1993;1993:2284–9.

88.

Muller JE, Ludmer PL, Willich SN, et al. Circadian variation in the frequency of sudden cardiac death. Circulation. 1987;75:131–8.PubMed

89.

Yamashita T, Murakawa Y, Sezaki K, et al. Circadian variation of paroxysmal atrial fibrillation. Circulation. 1997;96:1537–41.PubMed

90.

Yamashita T, Murakawa Y, Hayami N, et al. Relation between aging and circadian variation of paroxysmal atrial fibrillation. Am J Cardiol. 1998;82:1364–7.PubMedCrossRef

91.

Yamashita T, Sekiguchi A, Iwasaki YK, et al. Circadian variation of cardiac K⁺ channel gene expression. Circulation. 2003;107:1917–22.PubMedCrossRef

92.

Meredith AL, Wiler SW, Miller BH, et al. BK calcium-activated potassium channels regulate circadian behavioral rhythms and pacemaker output. Nat Neurosci. 2006;9:1041–9.PubMedCrossRef

93.

Kuhlman SJ, McMahon DG. Encoding the ins and outs of circadian pacemaking. J Biol Rhythms. 2006;21:470–81.PubMedCrossRef

94.

Inouye ST, Kawamura H. Persistence of circadian rhythmicity in a mammalian hypothalamic “island” containing the suprachiasmatic nucleus. Proc Natl Aad Sci U S A. 1979;76:5962–6.CrossRef

95.

Ko GY, Ko M, Dryer SE. Circadian and cAMP-dependent modulation of retinal cone cGMP-gated channels does not require protein synthesis or calcium influx through L-type channels. Brain Res. 2004;1021:277–80.PubMedCrossRef

96.

Ko ML, Liu Y, Dryer SE, Ko GY. The expression of L-type voltage-gated calcium channels in retinal photoreceptors is under circadian control. J Neurochem. 2007;103:784–92.PubMedCrossRef

Titel: Linking the Cardiomyocyte Circadian Clock to Myocardial Metabolism
verfasst von: David J. Durgan
Martin E. Young
Publikationsdatum: 01.04.2008
Verlag: Springer US
Erschienen in: Cardiovascular Drugs and Therapy / Ausgabe 2/2008
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI: https://doi.org/10.1007/s10557-008-6086-y

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Linking the Cardiomyocyte Circadian Clock to Myocardial Metabolism

Abstract

Introduction

Discussion

Conclusion

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Introduction

Discussion

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2008

Abstracts of the 5th International Conference of the Society for Heart and Vascular Metabolism

Epicardial Fat from Guinea Pig: A Model to Study the Paracrine Network of Interactions between Epicardial Fat and Myocardium?

What are the Biochemical Mechanisms Responsible for Enhanced Fatty Acid Utilization by Perfused Hearts from Type 2 Diabetic db/db Mice?

Metabolic (In)Flexibility of the Diabetic Heart

Glucose-Insulin Therapy, Plasma Substrate Levels and Cardiac Recovery After Cardiac Ischemic Events

Medium-chain Fatty Acids as Metabolic Therapy in Cardiac Disease

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie